Home Cart Sign in  
Chemical Structure| 911222-45-2 Chemical Structure| 911222-45-2

Structure of Rabusertib
CAS No.: 911222-45-2

Chemical Structure| 911222-45-2

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Rabusertib (LY2603618) is a potent and selective Chk1 inhibitor with an IC50 of 7 nM.

Synonyms: LY2603618; IC-83

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Rabusertib

CAS No. :911222-45-2
Formula : C18H22BrN5O3
M.W : 436.30
SMILES Code : O=C(NC1=NC=C(C)N=C1)NC2=CC(Br)=C(C)C=C2OC[C@@H]3CNCCO3
Synonyms :
LY2603618; IC-83
MDL No. :MFCD18633253
InChI Key :SYYBDNPGDKKJDU-ZDUSSCGKSA-N
Pubchem ID :11955855

Safety of Rabusertib

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

Target
  • Chk1

    Chk1, IC50:7 nM

In Vitro:

Cell Line
Concentration Treated Time Description References
ID8agg cells 2.5 μM 72 h Rabusertib induced DNA damage and increased γH2AX expression PMC9099860
T24 cells 80 μM 96 h Cefepime significantly improved the efficacy of the Chk1 inhibitor prexasertib PMC9099860
ID8agg cells 80 μM 96 h Cefepime significantly improved the efficacy of the Chk1 inhibitor rabusertib PMC9099860
PDAC cell lines 125 nM to 1 µM 24 h To determine the inhibitory effect of Rabusertib on PDAC cells, results showed that Rabusertib significantly reduced cell survival. PMC8014995
ID8agg cells 2.5 μM 72 h Rabusertib induced DNA damage and increased PDL1 expression, while Cefepime significantly reduced PDL1 expression and induced γH2AX, indicating its ability to overcome PDL1 overexpression caused by DNA damage. PMC9099860
T24 cells 80 μM 96 h Cefepime strikingly improved the efficacy of the Chk1i prexasertib, indicating its ability to enhance sensitivity to DNA-damaging agents. PMC9099860
ID8agg cells 80 μM 96 h Cefepime strikingly improved the efficacy of the Chk1i rabusertib, indicating its ability to enhance sensitivity to DNA-damaging agents. PMC9099860
CRC-SCs 50 µM 72 h To evaluate the effect of Rabusertib on cell proliferation and survival of CRC-SCs, the results showed that Rabusertib significantly affected the survival rate of CRC-SCs. PMC8257675
SW837 0.025 μM SN-38 72 h To validate the combined effect of Rabusertib and SN-38, results showed that the combination effect is primarily mediated through CHEK1 inhibition. PMC8891012
SNU-81 0.025 μM SN-38 72 h To validate the combined effect of Rabusertib and SN-38, results showed that the combination effect is primarily mediated through CHEK1 inhibition. PMC8891012

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice DLBCL xenograft model Intraperitoneal injection 90 mg/kg Twice a week, monitoring tumor growth Evaluate the synergy of SUMOi and CHK1i PMC10493575
Mice T24 cell xenograft model Intraperitoneal injection 2.5 mg/kg Daily, continuous treatment Cefepime significantly improved the efficacy of rabusertib and prolonged mouse survival PMC9099860
mice NSG mice intraperitoneal injection 2.5 mg/kg once daily, until the end of the experiment Cefepime significantly improved the efficacy of the Chk1i rabusertib, significantly prolonging the survival of mice. PMC9099860
NOD/SCID mice Colon cancer xenograft model Oral Rabusertib, intraperitoneal Irinotecan 200 mg/kg Daily Rabusertib, twice weekly Irinotecan, for 24-35 days To validate the combined effect of Rabusertib and Irinotecan, results showed that the combination therapy significantly inhibited tumor growth. PMC8891012

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.29mL

0.46mL

0.23mL

11.46mL

2.29mL

1.15mL

22.92mL

4.58mL

2.29mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories